Publications in collaboration with researchers from Hospital General Universitario Gregorio Marañón (48)

2023

  1. A Clinical-Genetic Risk Score for Predicting Cancer-Associated Venous Thromboembolism: A Development and Validation Study Involving Two Independent Prospective Cohorts

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 16, pp. 2911-2925

  2. Ambulatory cancer patients: who should definitely receive antithrombotic prophylaxis and who should never receive

    Internal and Emergency Medicine, Vol. 18, Núm. 6, pp. 1619-1634

  3. Bleeding risk with concomitant administration of VEGF-TKIs and anticoagulant agents

    Seminars in Oncology, Vol. 50, Núm. 3-5, pp. 67-70

  4. Ictus asociado a cáncer: estudio de prevalencia y factores predictores entre pacientes con ictus isquémico

    Revista de neurologia, Vol. 76, Núm. 6, pp. 189-195

  5. Immune checkpoint inhibitor-associated thrombosis in patients with bladder and kidney cancer: a study of the Spanish Society of Medical Oncology (SEOM) thrombosis and cancer group

    Clinical and Translational Oncology, Vol. 25, Núm. 10, pp. 3021-3031

  6. Prediction of serious complications in patients with pulmonary thromboembolism and solid cancer: Validation of the EPIPHANY Index in a prospective cohort of patients from the PERSEO study

    PLoS ONE, Vol. 18, Núm. 5 May

  7. Validation of the CoVID-TE model as a tool to predict thrombosis, bleeding, and mortality in the oncology patient with Sars-Cov-2 infection: a study by the SEOM cancer and thrombosis group

    Clinical and Translational Oncology

2022

  1. 2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19

    The Lancet Oncology, Vol. 23, Núm. 7, pp. e334-e347

  2. Apixaban and Dalteparin for the Treatment of Venous Thromboembolism in Patients with Different Sites of Cancer

    Thrombosis and Haemostasis, Vol. 122, Núm. 5, pp. 796-807

  3. Consensus on prevention and treatment of cancer-associated thrombosis (CAT) in controversial clinical situations with low levels of evidence

    European Journal of Internal Medicine, Vol. 100, pp. 33-45

  4. Do Antiangiogenics Promote Clot Instability? Data from the TESEO Prospective Registry and Caravaggio Clinical Trial

    Thrombosis and haemostasis, Vol. 122, Núm. 10, pp. 1653-1661

  5. Incidence, risk factors, and evolution of venous thromboembolic events in patients diagnosed with pancreatic carcinoma and treated with chemotherapy on an outpatient basis

    European Journal of Internal Medicine, Vol. 105, pp. 30-37

  6. Recurrent venous thromboembolism and major bleeding in patients with localised, locally advanced or metastatic cancer: an analysis of the Caravaggio study

    European Journal of Cancer, Vol. 165, pp. 136-145

  7. The Homologous Recombination Deficiency Scar in Advanced Cancer: Agnostic Targeting of Damaged DNA Repair

    Cancers, Vol. 14, Núm. 12

  8. Treatment modalities in cancer-associated venous thromboembolism (VTE)

    Best Practice and Research: Clinical Haematology, Vol. 35, Núm. 1

  9. Venous thromboembolism incidence in cancer patients with germline BRCA mutations

    Clinical and Translational Oncology, Vol. 24, Núm. 1, pp. 154-158

  10. Venous thromboembolism risk, prophylaxis and management in cancer patients with COVID-19: An unmet medical need

    Thrombosis Update, Vol. 6

2021

  1. Early clinical experience with trifluridine/tipiracil for refractory metastatic colorectal cancer: The ros study

    Cancers, Vol. 13, Núm. 18

  2. Effects of concomitant administration of anticancer agents and apixaban or dalteparin on recurrence and bleeding in patients with cancer-associated venous thromboembolism

    European Journal of Cancer, Vol. 148, pp. 371-381

  3. Incorporating genetic and clinical data into the prediction of thromboembolism risk in patients with lymphoma

    Cancer Medicine, Vol. 10, Núm. 21, pp. 7585-7592